Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Mark Exley"'
Autor:
David Andrews, Mark Exley, Charles Scott, Jenny Zilberberg, Amelia Zellander, Kenneth Kirby, Christopher Uhl, Christopher Cultrara
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/20e397c8f37e4e6e9cd181847ee0c01d
Autor:
Burcu Yigit, Xavier Michelet, Shalu Kharkwal, Eleni Chantzoura, Jan Bergmann, Alvaro Sebastian Yague, Simon Yue, Darrian Moskowitz, Benjamin Wolf, Mark Exley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/4ab76f12bd9144fb9d338dd4263b7af5
Autor:
Amelia Zellander, Christopher Uhl, Christopher Cultrara, Kenneth Kirby, Essam Elrazaq, Charles Scott, David Andrews, Jenny Zilberberg, Mark Exley
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Christopher Cultrara, Kenneth Kirby, Essam Elrazaq, Christopher Uhl, Amelia Zellander, Lorenzo Galluzzi, Mark Exley, Jenny Zilberberg
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Marco Purbhoo, Burcu Yigit, Xavier Michelet, Rachel Smith, Darrian Moskowitz, Maurice Kirby, Alexa Buffa, Sonia De Munari, Waldo Ortuzar Feliu, Koen Van Besien, Don Stevens, Mark Exley, Terese Hammond
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Don Stevens, Clifton Mo, Benjamin Garmezy, John Hamm, Benedito Carneiro, Breelyn Wilky, Rachel Sanborn, Anthony El- Khoueiry, Alexa Buffa, Sonia De Munari, Burcu Yigit, Marco Purbhoo, Mark Exley, David Einstein
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Christopher Cultrara, Kenneth Kirby, Essam Elrazaq, Christopher Uhl, Amelia Zellander, Lorenzo Galluzzi, Mark Exley, Jenny Zilberberg
Publikováno v:
Cancer Research. 83:1812-1812
Background: Imvax is developing a novel personalized immunotherapy platform that combines whole-tumor derived cells with an antisense oligonucleotide against insulin-like growth factor 1-receptor in implantable biodiffusion chambers (BDCs; 0.1 μm po
Publikováno v:
Cancer Research. 82:2782-2782
Background: IGV-001 is a novel immunotherapy that combines irradiated, patient-derived glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor (IMV-001) in biodiffusion chambers (BDC). We recently
Autor:
Jenny Zilberberg, Amelia Zellander, Christopher Uhl, Christopher Cultrara, Kenneth kirby, Essam Elazaq, Charles B. Scott, David W. Andrews, Mark Exley
Publikováno v:
Cancer Research. 82:626-626
Background: IGV-001 is a novel immunotherapy that combines irradiated patient-derived glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor (IMV-001) in biodiffusion chambers (BDC). We recently r
Autor:
Meenakshi, Subramanian, Radhika, Kini, Manasa, Madasu, Akiko, Ohta, Michael, Nowak, Mark, Exley, Michail, Sitkovsky, Akio, Ohta
Publikováno v:
European journal of immunology. 44(4)
Extracellular adenosine regulates inflammatory responses via the A2A adenosine receptor (A2AR). A2AR deficiency results in much exaggerated acute hepatitis, indicating nonredundancy of adenosine-A2AR pathway in inhibiting immune activation. To identi